MedellaNova — Non-invasive topical therapy for skin cancer

The most common cancers on Earth are still cut out by hand. We think the future of treating them is something you apply yourself.

the_problem

The most common cancers are still treated with a knife.

Basal cell and squamous cell carcinoma — together, keratinocyte carcinomas — are the most frequently diagnosed cancers in the United States. The standard of care works. It also costs.

Surgery is the default

Excision and Mohs surgery are effective but invasive — clinical procedures, healing time, and specialist access required.

Scarring & downtime

Procedures on the face, scalp, and hands carry cosmetic and functional consequences patients would rather avoid.

Uneven access

Surgical dermatology clusters in metro areas, leaving rural and underserved patients with limited, delayed options.

our_approach

A topical candidate designed to work where the cancer is.

A patient-applied topical therapy intended to act locally at the lesion site — no systemic exposure, no procedure. We're evaluating lotion and gel formulations for delivery and tolerability.

Non-invasive by design

Applied at home to the affected area — built around avoiding surgery, anesthesia, and recovery time.

Two formulations in evaluation

Lotion and gel candidates assessed for stability, application, and patient experience.

Engineered toward a clear endpoint

Development is structured around the regulatory and clinical milestones a topical oncology therapy must meet.

pipeline.status

Where we are — honestly.

MedellaNova is an early preclinical company. We're transparent about our stage: lab work is active, and the next milestones are funding-gated. Nothing below implies clinical proof of safety or efficacy.

Discovery

Complete

In vitro

Active now

In vivo

Funding-gated

IND-enabling

Planned

Phase 1

Target

evidence.log

What we've done — and what we haven't.

We separate evidence from intention, and we won't present early observations as clinical proof. Here's what's underway and what comes next.

Underway IN PROGRESS

In vitro studies on cell models
Formulation development — lotion and gel
IP strategy and patent counsel engagement
Regulatory and early clinical pathway planning

Not yet established PENDING

In vivo efficacy and safety data
IND-enabling toxicology
Controlled human clinical trial results
Demonstrated safety or efficacy in patients

founders

Science and strategy, paired.

Tyler Parker

CO-FOUNDER · STRATEGY & FINANCE

MBA in Data Analytics with a background in finance and corporate strategy. Leads capital, operations, and commercial direction.

Chris Groberg

CO-FOUNDER · SCIENCE

PhD candidate focused on skin cell biology and wound healing. Leads the scientific program and laboratory development.

open_channel

Let's build the non-invasive future.

We're in conversation with investors, scientific advisors, and partners interested in non-invasive dermatologic oncology.

hello@medellanova.com →